NSE: AJOONI
AJOONI BIOTECH LIMITED
Operates in the animal feed segment of the food products industry, with leadership that has over 15 years of experience in animal husbandry and agriculture. Revenue from operations in FY26 reached Rs. 182.38 crore, up 59% year-on-year, while net profit was Rs. 4.32 crore. Materials account for 81.2% of revenue, indicating a manufacturing-heavy cost base. The company is investing Rs. 18.03 crore in capex (9.9% of revenue), including a storage godown at Khanna, Punjab. It recently secured its biggest-ever order worth Rs. 47.52 crore, although the client, product and delivery timeline were not disclosed in the filing. AR · MarketPing reader · 2026-08-03
Revenue streams, as the annual report describes them. Animal feed and related products. Manufacturing-intensive, small-cap animal feed and food products company.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · standalone | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 74 | 74 | 80 | 115 | 182 |
| EBITDA (ex other income) | 3 | 3 | 2 | 4 | 6 |
| margin % | 4.2 | 3.7 | 2.8 | 3.2 | 3.4 |
| Owners' profit | 1 | 1 | 2 | 3 | 4 |
| EPS, as reported (₹) | 1.05 | 1.94 | 0.25 | 0.20 | 0.25 |
| ROE % · ROCE % | — · — | 0.0 · 0.0 | 5.1 · 8.0 | 3.8 · 5.2 | 4.7 · 7.0 |
| Debt / equity (x) | — | 0.12 | 0.05 | 0.02 | 0.19 |
| Cash from operations | 4 | (6) | (4) | (18) | (6) |
| Capex | (2) | (3) | 0 | (1) | (18) |
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 26 | 34 | 29 | 31 | 32 | 59 | 61 | 63 |
| Profit before tax | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 |
| Net profit | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 0 |
| EPS (₹) | 0.04 | 0.04 | 0.09 | 0.02 | 0.08 | 0.10 | 0.05 | 0.01 |
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| GODREJ AGROVET LIMITED | 11,129 | 24.9 | 5.14 | 13.1 | 20.6 | 17.6 | 10.3 | 8.9 |
| AVANTI FEEDS LIMITED | 9,109 | 17.1 | 2.46 | 9.6 | 17.7 | 23.5 | 8.1 | 9.0 |
| MUKKA PROTEINS LIMITED | 733 | 10.6 | 1.39 | 10.4 | 10.8 | 12.8 | — | 10.1 |
| KSE LTD. | 568 | 0.8 | 1.63 | — | 24.0 | 30.5 | — | (0.5) |
| SHIVAM CHEMICALS LIMITED | 247 | 29.6 | — | — | — | 17.8 | — | — |
| Mayank Cattle Food Limited | 68 | 9.0 | — | — | — | — | — | — |
| AJOONI BIOTECH LIMITED ◆ | 51 | 12.3 | 0.56 | — | 4.7 | 6.2 | — | 3.1 |
| NARMADA AGROBASE LIMITED | 42 | 55.9 | — | — | — | — | — | 5.5 |
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 12.3 | 14.7 | 4 of 8 | 57% |
| P/B | 0.6 | 1.6 | 1 of 5 | 100% |
| ROCE | 6.2 | 17.7 | 6 of 6 | 0% |
| ROE | 4.7 | 17.7 | 5 of 5 | 0% |
| Debt / Equity | 0.2 | 0.2 | 3 of 5 | 50% |
| EBITDA margin | 3.0 | 7.2 | 5 of 6 | 20% |
| Revenue growth | 103.1 | 51.8 | 2 of 6 | 80% |
| Profit growth | (44.7) | (37.4) | 4 of 5 | 25% |
| Market cap | 51 | 407 | 7 of 8 | 14% |
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 19 Oct 2026 · Company confirms functional website as per SEBI norms | compliance | minimal | — | — |
| 15 Oct 2026 · Confirmation Certificate filing under SEBI Regulation 74(5) for September 2026 quarter | compliance | minimal | — | — |
| 29 Sept 2026 · Trading Window Closure for Q2 FY2027 Results Declaration | compliance | minimal | — | — |
| 14 Aug 2026 · Ajooni Biotech Q1 FY27 revenue doubles YoY but profit drops | results | high | — | — |
| 14 Aug 2026 · Ajooni Biotech Q1 FY27: revenue doubles, profit halves | results | high | — | — |
| 12 Aug 2026 · Ajooni Biotech allots 90 lakh shares via preferential issue at Rs 4.30 | fund raising | high | — | — |
| 31 Jul 2026 · Authorized share capital raised to Rs 70 crore | corporate actions | medium | — | — |
| 31 Jul 2026 · Authorised share capital raised to Rs 70 crore | corporate actions | medium | — | — |
| 31 Jul 2026 · Ajooni Biotech approves preferential issue of 90 lakh shares at Rs 4.30 | fund raising | high | — | — |
| 31 Jul 2026 · Director Gursimran Singh re-appointed at AGM (retiring by rotation) | management changes | low | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.